Free Trial
NASDAQ:HOWL

Werewolf Therapeutics (HOWL) Stock Price, News & Analysis

Werewolf Therapeutics logo
$1.08 +0.01 (+1.03%)
Closing price 07/3/2025 03:40 PM Eastern
Extended Trading
$1.08 +0.00 (+0.28%)
As of 07/3/2025 04:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Werewolf Therapeutics Stock (NASDAQ:HOWL)

Key Stats

Today's Range
$1.06
$1.11
50-Day Range
$0.80
$1.42
52-Week Range
$0.60
$4.18
Volume
149,182 shs
Average Volume
438,052 shs
Market Capitalization
$48.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.33
Consensus Rating
Buy

Company Overview

Werewolf Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
62nd Percentile Overall Score

HOWL MarketRank™: 

Werewolf Therapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 386th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Werewolf Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Werewolf Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Werewolf Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Werewolf Therapeutics are expected to decrease in the coming year, from ($1.56) to ($1.92) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Werewolf Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Werewolf Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Werewolf Therapeutics has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Werewolf Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    5.56% of the float of Werewolf Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Werewolf Therapeutics has a short interest ratio ("days to cover") of 4.2.
  • Change versus previous month

    Short interest in Werewolf Therapeutics has recently decreased by 11.11%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Werewolf Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Werewolf Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.56% of the float of Werewolf Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Werewolf Therapeutics has a short interest ratio ("days to cover") of 4.2.
  • Change versus previous month

    Short interest in Werewolf Therapeutics has recently decreased by 11.11%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Werewolf Therapeutics this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Werewolf Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $435,273.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    23.60% of the stock of Werewolf Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    64.84% of the stock of Werewolf Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Werewolf Therapeutics' insider trading history.
Receive HOWL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Werewolf Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HOWL Stock News Headlines

Werewolf Therapeutics, Inc. (HOWL) - Yahoo Finance
Trump Makes Major Crypto Announcement
Pay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift all boats equally. They're wrong. One project stands to benefit more than any other – not by accident, but seemingly by design.
See More Headlines

HOWL Stock Analysis - Frequently Asked Questions

Werewolf Therapeutics' stock was trading at $1.48 at the start of the year. Since then, HOWL stock has decreased by 27.0% and is now trading at $1.0810.

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) posted its quarterly earnings results on Thursday, May, 8th. The company reported ($0.40) earnings per share for the quarter, beating analysts' consensus estimates of ($0.44) by $0.04.

Werewolf Therapeutics (HOWL) raised $101 million in an IPO on Friday, April 30th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, SVB Leerink and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

Shares of HOWL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Werewolf Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL).

Company Calendar

Last Earnings
5/08/2025
Today
7/05/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:HOWL
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.33
High Stock Price Target
$15.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+670.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$70.51 million
Pretax Margin
-6,335.17%

Debt

Sales & Book Value

Annual Sales
$1.88 million
Price / Cash Flow
N/A
Book Value
$1.65 per share
Price / Book
0.66

Miscellaneous

Free Float
34,284,000
Market Cap
$48.50 million
Optionable
Optionable
Beta
0.62
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:HOWL) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners